Plain-English translation of NCT05537896 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called Xerava () to see if it can prevent dangerous bacterial infections in patients with blood cancers who are undergoing chemotherapy or stem cell transplants. During these treatments, your white blood cell count drops very low, which makes your body vulnerable to infections. The study wants to find out how often breakthrough infections occur when patients receive this medication as a preventive measure.
Patients with acute leukemia and those receiving stem cell transplants face a serious risk of life-threatening infections when their white blood cell counts drop extremely low. Currently available preventive antibiotics have limitations—some don't cover resistant bacteria, and others don't reach all the right places in the body. This study is exploring whether this medication could be a better option because it fights a wider range of resistant bacteria and may work more effectively.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an IV infusion (through a vein) every 12 hours over 60 minutes while you are undergoing your leukemia treatment or stem cell transplant preparation. The study team will monitor you regularly to watch for any infections or side effects during this preventive treatment period. The research focuses on tracking whether you develop any breakthrough infections while receiving this medication.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States